PDF(Pubmed)
Abstract：
UNASSIGNED: To prospectively determine the median effective dose (ED50) of propofol for inhibiting a response to laryngeal mask airway (LMA) insertion when combined with different doses of esketamine in female patients.
UNASSIGNED: A total of 58 female patients (aged 20-60 years, ASAⅠ-Ⅱ) scheduled for elective hysteroscopy were enrolled and randomly divided into 2 groups, one of which was administered 0.2 mg/kg of esketamine (K1 group, n = 28) and the other 0.3 mg/kg of esketamine (K2 group, n = 30). The 2 groups received the corresponding doses of esketamine intravenously, followed by an intravenous injection of propofol (injection time was 30 s). The initial dose of propofol was 2 mg/kg, and the dose ratio of propofol in the adjacent patients was 0.9. If a positive reaction occurred due to LMA insertion, the dose ratio in the next patient was increased by 1 gradient; if not, the dose ratio was decreased by 1 gradient. The ED50, 95 % effective dose (ED95) and 95 % confidence interval (CI) of propofol for inhibiting a response to LMA insertion in the 2 esketamine groups were calculated using probit analysis.
UNASSIGNED: The ED50 of propofol for inhibiting a response to LMA insertion in female patients was 1.95 mg/kg (95 % CI, 1.82-2.08 mg/kg) in the K1 group and 1.60 mg/kg (95 % CI, 1.18-1.83 mg/kg) in the K2 group. The ED95 of propofol for inhibiting a response to LMA insertion in female patients was 2.22 mg/kg (95 % CI, 2.09-2.86 mg/kg) in the K1 group and 2.15 mg/kg (95 % CI, 1.88-3.09 mg/kg) in the K2 group.
UNASSIGNED: Propofol combined with 0.3 mg/kg of esketamine has low ED50 and ED95 effective doses for inhibiting an LMA insertion response in female patients undergoing hysteroscopy and surgery. There were no significant adverse effects, but the additional dose of propofol and airway pressure were significantly higher than those in the group administered 0.2 mg/kg of esketamine. Based on the results, we recommend the combination of propofol with 0.2 mg/kg esketamine for optimal conditions during LMA insertion in women undergoing hysteroscopy.
UNASSIGNED: A total of 58 female patients (aged 20-60 years, ASAⅠ-Ⅱ) scheduled for elective hysteroscopy were enrolled and randomly divided into 2 groups, one of which was administered 0.2 mg/kg of esketamine (K1 group, n = 28) and the other 0.3 mg/kg of esketamine (K2 group, n = 30). The 2 groups received the corresponding doses of esketamine intravenously, followed by an intravenous injection of propofol (injection time was 30 s). The initial dose of propofol was 2 mg/kg, and the dose ratio of propofol in the adjacent patients was 0.9. If a positive reaction occurred due to LMA insertion, the dose ratio in the next patient was increased by 1 gradient; if not, the dose ratio was decreased by 1 gradient. The ED50, 95 % effective dose (ED95) and 95 % confidence interval (CI) of propofol for inhibiting a response to LMA insertion in the 2 esketamine groups were calculated using probit analysis.
UNASSIGNED: The ED50 of propofol for inhibiting a response to LMA insertion in female patients was 1.95 mg/kg (95 % CI, 1.82-2.08 mg/kg) in the K1 group and 1.60 mg/kg (95 % CI, 1.18-1.83 mg/kg) in the K2 group. The ED95 of propofol for inhibiting a response to LMA insertion in female patients was 2.22 mg/kg (95 % CI, 2.09-2.86 mg/kg) in the K1 group and 2.15 mg/kg (95 % CI, 1.88-3.09 mg/kg) in the K2 group.
UNASSIGNED: Propofol combined with 0.3 mg/kg of esketamine has low ED50 and ED95 effective doses for inhibiting an LMA insertion response in female patients undergoing hysteroscopy and surgery. There were no significant adverse effects, but the additional dose of propofol and airway pressure were significantly higher than those in the group administered 0.2 mg/kg of esketamine. Based on the results, we recommend the combination of propofol with 0.2 mg/kg esketamine for optimal conditions during LMA insertion in women undergoing hysteroscopy.
摘要：
■前瞻性确定女性患者与不同剂量的艾氯胺酮联用时，异丙酚抑制喉罩气道（LMA）插入反应的中位有效剂量（ED50）。
■共58名女性患者（年龄20-60岁，ASAⅠ-Ⅱ)择期宫腔镜检查,随机分为2组,其中之一是服用0.2mg/kg的艾氯胺酮（K1组，n=28）和其他0.3mg/kg的艾氯胺酮（K2组，n=30)。两组分别静脉注射相应剂量的艾氯胺酮,随后静脉注射丙泊酚（注射时间为30s）。异丙酚的初始剂量为2mg/kg，相邻患者的丙泊酚剂量比为0.9。如果由于LMA插入而发生阳性反应，下一个患者的剂量比增加1个梯度；如果没有，剂量比下降1个梯度。使用概率分析计算了2个艾氯胺酮组中异丙酚抑制LMA插入反应的ED50，95％有效剂量（ED95）和95％置信区间（CI）。
■异丙酚抑制女性患者LMA插入反应的ED50在K1组为1.95mg/kg（95％CI，1.82-2.08mg/kg），在K2组为1.60mg/kg（95％CI，1.18-1.83mg/kg）。异丙酚抑制女性患者LMA插入反应的ED95在K1组为2.22mg/kg（95％CI，2.09-2.86mg/kg），在K2组为2.15mg/kg（95％CI，1.88-3.09mg/kg）。
■丙泊酚联合0.3mg/kg的艾氯胺酮具有较低的ED50和ED95有效剂量，可以抑制接受宫腔镜检查和手术的女性患者的LMA插入反应。没有明显的不良反应,但额外剂量的异丙酚和气道压力显著高于给予0.2mg/kg的艾氯胺酮组.根据结果,在接受宫腔镜检查的女性患者中,我们推荐丙泊酚与0.2mg/kg艾氯胺酮的联合应用,以获得最佳条件.
■共58名女性患者（年龄20-60岁，ASAⅠ-Ⅱ)择期宫腔镜检查,随机分为2组,其中之一是服用0.2mg/kg的艾氯胺酮（K1组，n=28）和其他0.3mg/kg的艾氯胺酮（K2组，n=30)。两组分别静脉注射相应剂量的艾氯胺酮,随后静脉注射丙泊酚（注射时间为30s）。异丙酚的初始剂量为2mg/kg，相邻患者的丙泊酚剂量比为0.9。如果由于LMA插入而发生阳性反应，下一个患者的剂量比增加1个梯度；如果没有，剂量比下降1个梯度。使用概率分析计算了2个艾氯胺酮组中异丙酚抑制LMA插入反应的ED50，95％有效剂量（ED95）和95％置信区间（CI）。
■异丙酚抑制女性患者LMA插入反应的ED50在K1组为1.95mg/kg（95％CI，1.82-2.08mg/kg），在K2组为1.60mg/kg（95％CI，1.18-1.83mg/kg）。异丙酚抑制女性患者LMA插入反应的ED95在K1组为2.22mg/kg（95％CI，2.09-2.86mg/kg），在K2组为2.15mg/kg（95％CI，1.88-3.09mg/kg）。
■丙泊酚联合0.3mg/kg的艾氯胺酮具有较低的ED50和ED95有效剂量，可以抑制接受宫腔镜检查和手术的女性患者的LMA插入反应。没有明显的不良反应,但额外剂量的异丙酚和气道压力显著高于给予0.2mg/kg的艾氯胺酮组.根据结果,在接受宫腔镜检查的女性患者中,我们推荐丙泊酚与0.2mg/kg艾氯胺酮的联合应用,以获得最佳条件.
